Latest news with #TALE
Newsweek
24-05-2025
- Entertainment
- Newsweek
The Handmaid's Tale Season 6 Episode 10 – Release Date, Schedule, Where To Watch
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Entertainment gossip and news from Newsweek's network of contributors We have arrived at the grand finale of The Handmaid's Tale, with episode ten of season six approaching on Tuesday, May 27. It has been a rollercoaster ride of a season, and now audiences get to see what the eight-year-long television show has been leading to in the final episode, titled "The Handmaid's Tale". As per the episode's official synopsis, June will reflect on her experiences in Gilead and decide what she will do next. THE HANDMAID'S TALE – 'Execution' – June faces her biggest challenge as Gilead cracks down on the rebels. THE HANDMAID'S TALE – 'Execution' – June faces her biggest challenge as Gilead cracks down on the rebels. Disney/Steve Wilkie READ: A Nice Indian Boy Gets New Digital Release Date – Where To Watch You are not going to want to miss the long-awaited finale, so to help you, we've got all the information on how to watch The Handmaid's Tale season six finale, including The Handmaid's Tale season six finale release time and The Handmaid's Tale season six finale release date. The Handmaid's Tale Season 6 Episode 10 Release Date The Handmaid's Tale season six, episode ten, releases May 27, 2025. New episodes of The Handmaid's Tale season six air weekly on Tuesdays through May 27, 2025. The Handmaid's Tale Season 6 Episode 10 – How to Watch The Handmaid's Tale season six finale will be available to stream on Hulu from 9 pm Pacific Time (PT) on May 26, 2025/Midnight Eastern Time (ET) on May 27. To watch The Handmaid's Tale season six finale, you will need a Hulu subscription. A monthly subscription is $9.99, or you can get the Disney Bundle, which includes Hulu, Disney+, and either ESPN+ or Max. That starts at $16.99 per month. What Time Does The Handmaid's Tale Season 6 Episode 10 Come Out? The Handmaid's Tale season six, episode ten, will be released at 9 pm Pacific Time on May 26/Midnight Eastern Time on May 27, 2025. New episodes of The Handmaid's Tale debut at different times depending on your time zone due to the late PT release. Here's what time new episodes become available globally: May 27 BRT : 1:00 am : 1:00 am BST : 5:00 am : 5:00 am CEST : 6:00 am : 6:00 am IST : 9:30 pm : 9:30 pm JST : 1:00 pm : 1:00 pm AET : 2:00 pm : 2:00 pm NZST: 4:00 pm The Handmaid's Tale Season 6 Episode 10 Runtime The official runtime for the season finale of The Handmaid's Tale season six is unavailable. So far this season, episodes have been between 39 and 57 minutes long. What Will Happen in The Handmaid's Tale Season 6 Finale? The official synopsis for The Handmaid's Tale season six finale reads: June reflects on her experiences in Gilead and decides what to do next. The episode is titled "The Handmaid's Tale". Synopses for previous episodes in season six of The Handmaid's Tale are as follows: Episode One: June and Serena's journey takes an unexpected turn. Moira makes a bold decision. Nick deals with a powerful visitor. June and Serena's journey takes an unexpected turn. Moira makes a bold decision. Nick deals with a powerful visitor. Episode Two: June tries to settle in a new community. Serena seeks a sanctuary. Luke and Moira take a big risk. June tries to settle in a new community. Serena seeks a sanctuary. Luke and Moira take a big risk. Episode Three: June struggles to save her loved ones. Commander Lawrence welcomes diplomats to New Bethlehem. Aunt Lydia searches for Janine. June struggles to save her loved ones. Commander Lawrence welcomes diplomats to New Bethlehem. Aunt Lydia searches for Janine. Episode Four: June disrupts the rebels' plans. Commander Lawrence gains power and influence. June disrupts the rebels' plans. Commander Lawrence gains power and influence. Episode Five: June and Moira go undercover. Serena and Nick make consequential choices. June and Moira go undercover. Serena and Nick make consequential choices. Episode Six: June hides in an unexpected place. June hides in an unexpected place. Episode Seven: After a shocking revelation, June spirals. Serena plans for a prestigious future. After a shocking revelation, June spirals. Serena plans for a prestigious future. Episode Eight: June and Moira execute their dangerous plan. Serena makes a big commitment. June and Moira execute their dangerous plan. Serena makes a big commitment. Episode Nine: June faces her biggest challenge as Gilead cracks down on the rebels. (as per IMDb) Will There Be a Season 7 of The Handmaid's Tale? No. Season six will be the final season of The Handmaid's Tale.
Newsweek
17-05-2025
- Entertainment
- Newsweek
The Handmaid's Tale Season 6 Episode 9 – Release Date, Schedule, Where To Watch
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Entertainment gossip and news from Newsweek's network of contributors June is set to face her biggest challenge yet as Gilead prepares to crack down on the rebels, Hulu reveals in the official synopsis for episode nine of season six of The Handmaid's Tale. The new episode is the penultimate of the series, and audiences are going to want to be the first to tune in on Tuesday, May 20, as the season (and the series) prepare to come to a close. MADELINE BREWER, SAMIRA WILEY, D'ARCY CARDEN in THE HANDMAID'S TALE – 'Execution' – June faces her biggest challenge as Gilead cracks down on the rebels. MADELINE BREWER, SAMIRA WILEY, D'ARCY CARDEN in THE HANDMAID'S TALE – 'Execution' – June faces her biggest challenge as Gilead cracks down on the rebels. Disney/Steve Wilkie READ: A Nice Indian Boy Gets New Digital Release Date – Where To Watch We have all the information below on how to watch The Handmaid's Tale season six, episode nine, including The Handmaid's Tale season six, episode nine release time and The Handmaid's Tale season six, episode nine release date. The Handmaid's Tale Season 6 Episode 9 Release Date The Handmaid's Tale season six, episode nine, releases May 20, 2025. New episodes of The Handmaid's Tale season six air weekly on Tuesdays through May 27, 2025. The Handmaid's Tale Season 6 Episode 9 – How to Watch The Handmaid's Tale season six, episode nine, will be available to stream on Hulu from 9 pm Pacific Time (PT) on May 19, 2025/Midnight Eastern Time (ET) on May 20. To watch The Handmaid's Tale, you will need a Hulu subscription. A monthly subscription is $9.99, or you can get the Disney Bundle, which includes Hulu, Disney+, and either ESPN+ or Max. That starts at $16.99 per month. What Time Does The Handmaid's Tale Season 6 Episode 9 Come Out? The Handmaid's Tale season six, episode nine, will be released at 9 pm Pacific Time on May 19/Midnight Eastern Time on May 20, 2025. New episodes of The Handmaid's Tale debut at different times depending on your time zone due to the late PT release. Here's what time new episodes become available globally: May 20 BRT : 1:00 am : 1:00 am BST : 5:00 am : 5:00 am CEST : 6:00 am : 6:00 am IST : 9:30 pm : 9:30 pm JST : 1:00 pm : 1:00 pm AET : 2:00 pm : 2:00 pm NZST: 4:00 pm The Handmaid's Tale Season 6 Episode 9 Runtime The official runtime for episode nine of The Handmaid's Tale season six is unavailable. So far this season, episodes have been between 39 and 55 minutes long. What Will Happen in The Handmaid's Tale Season 6 Episode 9? The official synopsis for The Handmaid's Tale season six, episode nine reads: June faces her biggest challenge as Gilead cracks down on the rebels. The episode is titled "Execution". Synopses for previous episodes in season six of The Handmaid's Tale are as follows: Episode One: June and Serena's journey takes an unexpected turn. Moira makes a bold decision. Nick deals with a powerful visitor. June and Serena's journey takes an unexpected turn. Moira makes a bold decision. Nick deals with a powerful visitor. Episode Two: June tries to settle in a new community. Serena seeks a sanctuary. Luke and Moira take a big risk. June tries to settle in a new community. Serena seeks a sanctuary. Luke and Moira take a big risk. Episode Three: June struggles to save her loved ones. Commander Lawrence welcomes diplomats to New Bethlehem. Aunt Lydia searches for Janine. June struggles to save her loved ones. Commander Lawrence welcomes diplomats to New Bethlehem. Aunt Lydia searches for Janine. Episode Four: June disrupts the rebels' plans. Commander Lawrence gains power and influence. June disrupts the rebels' plans. Commander Lawrence gains power and influence. Episode Five: June and Moira go undercover. Serena and Nick make consequential choices. June and Moira go undercover. Serena and Nick make consequential choices. Episode Six: June hides in an unexpected place. June hides in an unexpected place. Episode Seven: After a shocking revelation, June spirals. Serena plans for a prestigious future. After a shocking revelation, June spirals. Serena plans for a prestigious future. Episode Eight: June and Moira execute their dangerous plan. Serena makes a big commitment. (as per IMDb)
Yahoo
28-04-2025
- Business
- Yahoo
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the 'Company') (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated non-viral transgene insertion for advancing cellular and gene therapies, and advancements in genetic editing using TALE base editors (TALEB), at the Society of Gene and Cell Therapy (ASGCT) annual meeting, that will be held on May 13-17, 2025 in New Orleans. The data are presented in two posters: Title: TALEN®- Mediated non-viral Transgene Insertion for the Advancement of Cellular and Gene Therapies. Cell and gene therapy approaches can use gene-editing tools and introduce transgenes to modify disease-associated genes, thus providing a potential therapeutic solution for a wide array of diseases. In this work, Cellectis combines TALEN®-mediated gene editing with non-viral delivery of transgene for advancing cellular and gene therapies, and explores gene insertion-efficacy and cellular health using single-stranded DNA (ssDNA) for payload delivery in different cell types. This innovative approach has the potential to address the challenges associated with traditional lentiviral viral methods or AAV-mediated transgene insertion such as manufacturing constraints, potential genomic toxicities or limited payload size. Research data show: Non-viral methods for gene editing: TALEN® mediated gene editing combined with non-viral templates (linear and circular ssDNA) can be used for highly efficient gene insertion in T-cells as well as hematopoietic stem and progenitor cells (HSPCs) promoting viability and insertion specificity. Advantages of Circular ssDNA over viral vectors: Transcriptomic analysis and in vivo data demonstrate that CssDNA-mediated cell engineering allows better maintenance of HSPC fitness as well as more stable gene editing, compared to traditional viral donor template-mediated transgene delivery. « The implementation of these gene-editing techniques holds significant potential for the development of next-generation therapies, aiming to provide alternative efficient, and safe therapeutic options for patients with cancer, autoimmune diseases, monogenic disorders, and various other conditions. » said Beatriz Aranda Orgilles, Ph.D., Associate Director – IO and business development analyst at Cellectis. Title: High fidelity C-to-T editing with TALE base editors TALE base editors (TALEB) are fusions of a transcription activator-like effector domain (TALE), split-DddA deaminase halves, and a uracil glycosylase inhibitor (UGI). The C-to-T class of TALEB edits double-stranded DNA by converting a cytosine (C) to a thymine (T) and does not involve DNA strand nick. Cellectis has developed a method to characterize the efficiency of this conversion and examined various factors influencing TALEB activity. This method also takes advantage of a highly precise and efficient knock-in of ssODN in primary T cells to develop an assay to assess how the composition and spacer variations of target sequences affect TALEB activity/efficiency. Research data show: Efficiency of C-to-T editing: TALEB enables efficient conversion of C to T. Variations in target sequences and surrounding bases affecting editing efficiency. An educated choice of the TALEB architecture further allows to control the editing outcome. Assessment of off-target editing risks: Studies have been conducted to evaluate off-target editing, showing no detectable editing in primary cells at previously described sites, highlighting the specificity of TALEB for potential therapeutic applications. «It is inspiring to see the advancement of Cellectis' TALE technology into a new tool that is available in our gene editing toolbox. Our ability to understand and fine-tune the editing capacity of TALE base editors has equipped us with another efficient and specific approach that can be used to support novel gene editing and gene therapy applications. » said Louisa Mayer, Ph.D., Scientist II and Supervisor – Innovation & Gene Editing at Cellectis. Overall, the results of this study enhance the control and use of TALEB, allowing for the design of highly efficient and specific TALEB compatible with future therapeutic applications. The abstracts are live on the ASGCT website. The posters will be available on Cellectis' website the first day of the event. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on LinkedIn and X. TALEN® is a registered trademark owned by Cellectis. Cautionary Statement This press release contains 'forward-looking' statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as' can,' 'potential,' 'has the potential to,' 'aiming to,' and 'will' or the negative of these and similar expressions. These forward-looking statements are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of our innovation programs, in particular our gene editing innovations. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2024 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC's website at as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@ Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@ Attachment ASGCT posters announcement PR-ENGLISH(1)Sign in to access your portfolio
